These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 11997950)
1. Hyperhomocysteinemia in end stage renal disease: is treatment necessary? Snavely J Nephrol Nurs J; 2002 Apr; 29(2):155-60; quiz 161-2. PubMed ID: 11997950 [TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia in end-stage renal failure. Kes P Acta Med Croatica; 2000; 54(4-5):175-81. PubMed ID: 11379482 [TBL] [Abstract][Full Text] [Related]
3. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Suliman ME; Stenvinkel P; Bárány P; Heimbürger O; Anderstam B; Lindholm B Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961 [TBL] [Abstract][Full Text] [Related]
5. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198 [TBL] [Abstract][Full Text] [Related]
6. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients]. Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478 [TBL] [Abstract][Full Text] [Related]
7. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease. Palleschi S; De Angelis S; Rossi B; Diana L; Papa V; Severini G; Splendiani G Nephron Clin Pract; 2008; 108(2):c106-12. PubMed ID: 18212512 [TBL] [Abstract][Full Text] [Related]
8. Homocysteine: the latest risk factor for heart disease. Reeder SJ; Hoffmann RL; Magdic KS; Rodgers JM Dimens Crit Care Nurs; 2000; 19(1):22-8. PubMed ID: 10876482 [TBL] [Abstract][Full Text] [Related]
9. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Hyndman ME; Manns BJ; Snyder FF; Bridge PJ; Scott-Douglas NW; Fung E; Parsons HG Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627 [TBL] [Abstract][Full Text] [Related]
10. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation]. Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000 [TBL] [Abstract][Full Text] [Related]
11. It is important to lower homocysteine in dialysis patients. Zoccali C; Mallamaci F; Tripepi G Semin Dial; 2007; 20(6):530-3. PubMed ID: 17991199 [TBL] [Abstract][Full Text] [Related]
12. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680 [TBL] [Abstract][Full Text] [Related]
13. [Should patients with chronic renal insufficiency be treated with folic acid, vitamin B6 and vitamin B12?]. Birn H Ugeskr Laeger; 2008 Mar; 170(11):933-7. PubMed ID: 18397619 [TBL] [Abstract][Full Text] [Related]
14. Elevated homocysteine levels in patients with end-stage renal disease. Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160 [TBL] [Abstract][Full Text] [Related]
15. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754 [TBL] [Abstract][Full Text] [Related]
16. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?]. Lovcić V; Kes P; Zeljko R; Kusec V Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832 [TBL] [Abstract][Full Text] [Related]
17. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738 [TBL] [Abstract][Full Text] [Related]
18. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Qin X; Huo Y; Xie D; Hou F; Xu X; Wang X Clin Nutr; 2013 Oct; 32(5):722-7. PubMed ID: 23313356 [TBL] [Abstract][Full Text] [Related]
19. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173 [TBL] [Abstract][Full Text] [Related]
20. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Heinz J; Kropf S; Luley C; Dierkes J Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]